CD3-bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory

Immunotherapy of cancer with CD3-targeting bispecific antibodies ( CD3bsAb) is a fast developing field and multiple tumor-associated antigens (TAA) are evaluated for hematological and solid malignancies. The efficacy of these CD3bsAb is usually examined in xenograft mouse tumor models with human T cells or in genetically engineered mouse models, where human TAA are introduced. These models often fail to fully recapitulate the natural tumor environment, especially for solid cancers, because of interspecies differences. Here, we investigated the systemic and intra-tumoral effects of a mouse CD3bsAb in a fully immune-competent mouse melanoma model. Systemic administration of 0.5 mg/kg antibody induced a brief overall T-cell activation that was selectively sustained in the tumor microenvironmentfor several days. A fast subsequent influx of inflammatory macrophages into the tumor microenvironmentwas observed, followed by an increase in the number of CD4+ and CD8+ T cells. Although the capacity to directly kill melanoma cells in vitro was very modest, optimal tumor elimination was observed in vivo, even in the absence of CD8+ T cells, implying a redundancy in T-cell subsets for therapeutic efficacy. Finally, we took advantage of the full immune-competence of our mouse model and tested immune memory induction. Despite a strong initial immunity against melanoma, treatment with the CD3bsAb did not install protective memory responses. The observed mechanisms of action revealed in this immune-competent mouse model might form a rational basis for combinatorial approaches.